KERX up +1.71% percent Today $KERX High is at 15.68 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 2:50 PM

KERX up +1.71% percent Today $KERX High is at 15.68 and the Low 15.41 with current volume of 303,422.

Recent News posted below.

Keryx Biopharmaceuticals KERX other info.
http://investorshangout.com/Keryx-Biopharmace...ERX-54563/

KERX Keryx Biopharmaceuticals Recent Headline News

Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST

OCN: 21.28 (+0.68), KOS: 9.50 (-0.16), KIN: 8.94 (+0.20), VSAT: 66.21 (-1.40), RFMD: 13.49 (-0.08), EBAY: 54.87 (+0.51), TQNT: 22.45 (-0.15), IDIX: 24.50 (+0.05), SEMI: 17.01 (-0.42), VRTV: 47.17 (+1.02), THRX: 13.25 (+0.02), TBPH: 17.37 (-0.11), IMOS: 21.13 (-0.76), ELOS: 9.95 (-0.34), MU: 32.28 (-0.34), AR: 52.66 (+0.15), NCQ: 0.71 (+0.02), PBF: 27.54 (+0.45), LNG: 72.19 (+0.33), ATRA: 24.43 (+1.26), KERX: 15.21 (unch), NG: 2.92 (+0.04), AOI: 1.85 (unch), FWP: 21.80 (-0.59), BYD: 11.64 (-0.42), ALDW: 17.38 (+0.25), SUNE: 16.50 (-0.43), MRK: 59.51 (+0.44), AVEO: 0.98 (+0.04), AIG: 53.98 (+0.08)

Keryx Bio presents Ferric Citrate safety data at ASN meeting
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:01AM CST

KERX: 15.21 (unch)

Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
GlobeNewswire - Sat Nov 15, 9:00AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company"

today announced results from a 48-week Open Label Extension (OLE) safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease (CKD) patients with elevated serum phosphorus levels, or hyperphosphatemia. The OLE findings were presented as a late-breaking poster (Abstract #SA-PO1102) at the 2014 American Society of Nephrology's (ASN) Kidney Week meeting in Philadelphia, PA. The results are consistent with those seen in the pivotal Phase 3 trial.
KERX: 15.21 (unch)

Keryx Biopharmaceuticals, Inc. to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Fri Nov 14, 7:30AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present a corporate overview at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York City.
KERX: 15.21 (unch)

'Mad Money' Lightning Round: Intel Is Underrated by Wall Street
at The Street - Tue Nov 11, 5:00AM CST
Cramer doesn't think now is a good time for Caterpillar.
KMI: 40.35 (+0.98), GD: 142.21 (-0.45), LMT: 185.52 (-1.08), RTN: 103.14 (-1.49), DDD: 35.60 (+1.53), NOC: 135.83 (-0.24), MO: 49.09 (+0.31), INTC: 34.17 (+0.22), KERX: 15.21 (unch), WPRT: 5.79 (-0.08), IBM: 164.59 (+0.43), MRK: 59.51 (+0.44), GM: 32.49 (+0.70), PG: 87.52 (-0.59), CAT: 101.95 (+0.61)

Cramer's Lightning Round - I Curse The Day I Bought General Motors (11/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Tue Nov 11, 3:18AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 10. Bullish Calls: Merck (NYSE: MRK ): Cramer prefers Merck to Procter & Gamble. Intel (NASDAQ: INTC ): "INTC is underrated...
GD: 142.21 (-0.45), LMT: 185.52 (-1.08), NOC: 135.83 (-0.24), DDD: 35.60 (+1.53), MO: 49.09 (+0.31), INTC: 34.17 (+0.22), HPQ: 37.41 (+0.49), KERX: 15.21 (unch), WPRT: 5.79 (-0.08), IBM: 164.59 (+0.43), MRK: 59.51 (+0.44), SSYS: 105.06 (+0.21), GM: 32.49 (+0.70), CAT: 101.95 (+0.61), LINE: 22.24 (-0.41), PG: 87.52 (-0.59)

Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 2.97 (-0.01), BIIB: 305.00 (-0.43), AMAG: 35.05 (+1.05), KERX: 15.21 (unch)

Nasdaq stocks posting largest percentage increases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ESYS: 17.33 (+0.01), SWIR: 38.56 (+0.25), PERI: 5.79 (+0.12), JIVE: 6.53 (-0.30), TREE: 46.55 (-0.85), KERX: 15.21 (unch), ECYT: 6.57 (+0.15), ADEP: 8.50 (-0.09), ABTL: 10.84 (-0.48), NDLS: 23.21 (-0.27), BSFT: 26.71 (-0.79), SW.TO: 43.62 (+0.45), CALD: 15.83 (-0.23), PLNR: 7.04 (+0.35)

Keryx's (KERX) CEO Ron Bentsur on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:50AM CST

KERX: 15.21 (unch)

Keryx Biopharmaceuticals (KERX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 6:55AM CST

KERX: 15.21 (unch)

Keryx Biopharma misses Street 3Q forecasts
Automated Insights - Thu Nov 06, 6:36AM CST
NEW YORK (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Thursday reported a third-quarter loss of $35.3 million.
KERX: 15.21 (unch)

Keryx Biopharmaceuticals EPS of -$0.38
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:04AM CST

KERX: 15.21 (unch)

Keryx Biopharmaceuticals, Inc. Announces Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Thu Nov 06, 6:00AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease (the "Company" or "Keryx"

, today announced its financial results for the third quarter ended September 30, 2014. At September 30, 2014, the Company had cash, cash equivalents, interest receivable and investment securities of $118.4 million, as compared to $55.7 million at December 31, 2013.
KERX: 15.21 (unch)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:30PM CST

CYNI: 2.71 (-0.04), AAP: 145.78 (+0.97), DNOW: 28.50 (+0.16), AAON: 20.48 (-0.48), CNQ: 35.74 (-0.26), HSP: 58.36 (+0.08), CNK: 35.63 (-0.03), AMSC: 0.98 (-0.05), AES: 13.71 (+0.24), MWIV: 157.95 (+2.90), BBG: 12.95 (-1.16), HZNP: 12.52 (+0.27), KATE: 28.87 (-0.06), MITL: 10.24 (+0.12), AEE: 43.04 (+0.83), HSIC: 130.63 (+0.48), HII: 107.98 (+0.13), NAVB: 1.26 (+0.10), CECE: 14.08 (-0.46), AKRX: 37.88 (-0.33), COTY: 19.02 (-0.13), GOLD: 69.25 (+0.50), IT: 86.06 (+0.01), HNR: 2.89 (-0.10), KERX: 15.21 (unch), CECO: 5.69 (-0.20), HSC: 19.94 (+0.44), AMRC: 8.03 (-0.06), KLIC: 13.80 (-0.16), GEO: 39.30 (-0.62), AINV: 8.18 (-0.01), BCE: 47.39 (+0.52), AZN: 72.44 (-0.41), BCRX: 10.21 (+0.14), CPN: 23.45 (-0.15), BR: 45.10 (+0.03), FUR: 16.96 (+0.11), LIN: 24.00 (-0.04), LMIA: 13.88 (+0.16), CDW: 32.81 (-0.14), CVC: 18.70 (+0.16), AAWW: 41.26 (-0.35), GNRC: 41.92 (+0.05), MPEL: 25.99 (-0.54), DTV: 86.99 (-0.56), APA: 72.41 (-0.94), CRZO: 50.25 (-1.34), BKCC: 8.94 (unch), ERJ: 36.95 (+0.19), AMCX: 62.38 (+0.52), LPI: 17.15 (-0.56), HAIN: 108.29 (+0.02), FSYS: 10.03 (-0.38), GLP: 43.39 (+1.09), AOL: 46.57 (+0.53), FUN: 46.74 (-0.12), BDBD: 9.81 (+0.14)

Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 88.24 (+0.13), ACT: 245.62 (+1.85), HSP: 58.36 (+0.08), KERX: 15.21 (unch)

Keryx Biopharmaceuticals Up 9.7% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Mon Nov 03, 11:18AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on October 2nd, 2014 at $15.03. In approximately 1 month, Keryx Biopharmaceuticals has returned 9.68% as of today's recent price of $16.48.
KERX: 15.21 (unch)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 101.03 (-1.03), CLVS: 53.98 (-0.91), ARWR: 5.92 (-0.12), ACHN: 13.25 (-0.72), MRK: 59.51 (+0.44), RTRX: 9.45 (-0.45), RGLS: 16.80 (-0.40), EPZM: 22.68 (-0.29), AGIO: 84.96 (+0.90), RMTI: 10.55 (+0.03), ARNA: 4.53 (unch), KERX: 15.21 (unch)

Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 30, 7:00AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, today announced that a conference call will be held on Thursday, November 6, 2014 at 8:00 a.m. ET to discuss results for the third quarter of 2014 and provide an update on the business.
KERX: 15.21 (unch)

Big Board Biotech Stocks in Play This Week
ACCESSWIRE - Tue Oct 28, 1:16PM CDT
Coral Gables, FL / ACCESSWIRE / October 28, 2014 / CytRx Corporation (NASDAQ: CYTR) announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society.
PACB: 7.04 (+0.24), CYTR: 2.78 (-0.01), KERX: 15.21 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Skiptown Expands in Georgia Amid Growing Demand

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...